Beef in an Optimal Lean Diet (BOLD) Effects on Metabolic Syndrome
BOLD-X
BOLD (Beef in an Optimal Lean Diet) Effects on Established and Emerging Cardiovascular Disease (CVD) Risk Factors: Effects on Metabolic Syndrome (BOLD-X)
1 other identifier
interventional
63
1 country
1
Brief Summary
The proposed research will provide important information about the role of 2 intervention diets that provide different amounts of lean beef and meet current nutrient recommendations for the treatment of Metabolic Syndrome (MetSyn), a chronic disease that is still increasing in prevalence at alarming rates. The experimental and diet designs will enable us to evaluate lifestyle interventions for MetSyn for persons who maintain weight, lose weight and maintain their weight loss, as is currently recommended in clinical practice. Importantly, the investigators will compare a diet high in lean beef (5 oz/day) which is compositionally similar (i.e., energy and nutrients) to the modified-DASH diet, a low beef diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors, including MetSyn. In addition, the investigators also will evaluate a moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet, on CVD risk factors in persons with MetSyn. A follow-up study was conducted to assess dietary compliance in a sub-sample of the population at 12-months; participants were not informed of this end-point and additional consent was obtained. Hypotheses:
- 1.Healthful isocaloric diets that include lean beef as the primary source of protein (BOLD diet) with average (18%; BOLD) or moderate-high (28%; BOLD+) total protein intake will show similar or greater reductions in CVD risk, respectively when compared to a modified-DASH diet.
- 2.A healthful weight-loss diet, including lean beef as the primary source of protein in a high-moderate protein diet (BOLD+ diet), plus regular exercise (BOLD+ + ex) will reduce body weight equal to that of a BOLD + ex and DASH + ex intervention, but may improve CV risk factors (such as BP and TG), and therefore reduce the prevalence of MetSyn more than a BOLD + ex and DASH + ex intervention.
- 3.The BOLD diet will be more effective than the modified-DASH diet, and the BOLD+ diet more effective than the BOLD diet in maintaining the CVD benefits attained during phases 1 and 2. Dietary adherence will be better on the BOLD and BOLD + diets compared with the modified DASH diet.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2009
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2009
CompletedFirst Submitted
Initial submission to the registry
June 18, 2009
CompletedFirst Posted
Study publicly available on registry
July 13, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2012
CompletedAugust 21, 2023
August 1, 2023
2.5 years
June 18, 2009
August 16, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Criteria for Metabolic Syndrome: central obesity (weight, waist circumference, abdominal obesity), TG, HDL-C, glucose and BP
2 weeks
Criteria for Metabolic Syndrome: central obesity (weight, waist circumference, abdominal obesity), TG, HDL-C, glucose and BP
7 weeks
Criteria for Metabolic Syndrome: central obesity (weight, waist circumference, abdominal obesity), TG, HDL-C, glucose and BP
13 weeks
Criteria for Metabolic Syndrome: central obesity (weight, waist circumference, abdominal obesity), TG, HDL-C, glucose and BP
24 weeks
Secondary Outcomes (14)
Vascular endothelial function measured by endo-PAT
2 weeks
Lipids and lipoproteins
2 weeks
Inflammatory markers
2 weeks
Vascular endothelial function measured by endo-PAT
7 weeks
Vascular endothelial function measured by endo-PAT
13 weeks
- +9 more secondary outcomes
Study Arms (3)
Modified-DASH Diet
EXPERIMENTALBOLD diet
EXPERIMENTALBOLD-X
EXPERIMENTALInterventions
Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
Eligibility Criteria
You may qualify if:
- (BMI 27-42 kg/m2)
- Three or more of the following risk factors (defined as having MetSyn):
- abdominal obesity \[waist circumference \> 102 cm (40 inches) in men and \> 88 cm (35 inches) in women\],
- elevated blood glucose \[\> 110mg/dl (6.1 mmol/L)\]
- elevated TG \[\>150 mg/dl (1.7 mmol/L)\]
- low HDL-C \[\<40 mg/dl (1.03 mmol/L) in men and \<50 mg/dL (1.29 mmol/l) in women\]
- hypertension (Systolic Blood Pressure \> 130 mmHg or Diastolic Blood Pressure \> 85 mmHg)\*
- BP medication accepted if BP stable and less than 160/100mm Hg
You may not qualify if:
- A history of myocardial infarction, stroke, diabetes mellitus, liver disease, kidney disease, and thyroid disease (unless controlled on medication)
- Lactation, pregnancy, or desire to become pregnant during the study
- Intake of putative cholesterol-lowering supplements (psyllium, fish oil capsules, soy lecithin, niacin, fiber, flax, and phytoestrogens, stanol/sterol supplemented foods)
- High alcohol consumption (≥ 14 drinks/week)
- Participation in regular physical activity (\> 1 formal session/week)
- Lipid or glucose lowering medication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Penn State University
University Park, Pennsylvania, 16802, United States
Related Publications (1)
Hill AM, Harris Jackson KA, Roussell MA, West SG, Kris-Etherton PM. Type and amount of dietary protein in the treatment of metabolic syndrome: a randomized controlled trial. Am J Clin Nutr. 2015 Oct;102(4):757-70. doi: 10.3945/ajcn.114.104026. Epub 2015 Sep 9.
PMID: 26354540DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Penny M Kris-Etherton, PhD
Penn State University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 18, 2009
First Posted
July 13, 2009
Study Start
February 1, 2009
Primary Completion
August 1, 2011
Study Completion
March 1, 2012
Last Updated
August 21, 2023
Record last verified: 2023-08